CRISPR Just Fixed a Genetic Disease in a Living Patient for the First Time
CRISPR was used to fix a genetic disease inside a living patient for the first time, reducing misfolded proteins by 93% with one injection.
The One-Shot Cure
In a clinical trial at University College London, CRISPR gene editing was used to correct the genetic mutation causing transthyretin amyloidosis — a fatal heart condition — directly in a living patient's liver cells. Six months after a single IV infusion, the patient's misfolded protein levels dropped 93%, effectively halting disease progression.
Previous CRISPR therapies (like Casgevy for sickle cell disease) required extracting cells, editing them in a lab, and reinfusing them. This is the first time CRISPR was delivered systemically — injected into the bloodstream — to edit genes inside the body.
The Delivery Breakthrough
The key innovation isn't the CRISPR mechanism itself but the delivery vehicle: lipid nanoparticles engineered to target liver cells specifically. These microscopic fat bubbles carry the CRISPR machinery through the bloodstream and release it only when absorbed by hepatocytes. The technology was developed by Intellia Therapeutics, building on the mRNA lipid nanoparticle platform that made COVID vaccines possible.
What This Opens Up
If in-vivo CRISPR works reliably, the implications are staggering. Over 7,000 known diseases are caused by single-gene mutations. Many affect organs — liver, brain, heart — where cell extraction and reinfusion isn't practical. Systemic CRISPR delivery could theoretically treat all of them with a single injection. The key word is "theoretically" — each disease requires its own guide RNA, delivery optimization, and safety testing. We're at the beginning of a very long road, but it's a road that didn't exist before this trial.